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ABSTRACT 13 
Whilst pharmaceuticals are now routinely detected in aquatic environments, we know little of 14 
the biological activity their presence might provoke. It is estimated that nearly 40% of all 15 
marketed pharmaceuticals are G protein-coupled receptors (GPCRs)-acting pharmaceuticals. 16 
Here, we applied an in vitro assay, called the TGFα shedding assay, to measure the biological 17 
activities of GPCRs-acting pharmaceuticals present in effluents from municipal wastewater 18 
treatment plants in the United Kingdom (UK) and Japan from 2014 to 2016. The results 19 
indicated that compounds were present in the wastewater with antagonistic activities against 20 
angiotensin (AT1), dopamine (D2), adrenergic (β1), acetylcholine (M1) and histamine (H1) 21 
receptors in both countries. The most consistent and powerful antagonistic activity was 22 
against the H1, D2, and AT1 receptors at up to µg-antagonist-equivalent quantity/L. Chemical 23 
analysis of the same UK samples were also conducted in parallel. Comparing the results of 24 
the bioassay with the chemical analysis indicated; 1) the existence of other D2 or M1 receptor 25 
antagonist(s) besides sulpiride (D2 antagonist) or pirenzepine (M1 antagonist) in wastewater; 26 
and 2) there might be a mixture effect between agonist and antagonistic activities against β1 27 
receptor. GPCR-acting pharmaceuticals should be paid more attention in the environmental 28 
monitoring and toxicity testing in future studies. 29 
30 
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32 
33 
34 
35 
36 
37 
38 
39 
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INTRODUCTION 41 
Pharmaceuticals have been widely detected in effluents from wastewater treatment plants 42 
(WWTPs) and river water.
1–7
 Because of their biological activity, concerns about their43 
potential risks to aquatic organisms have been raised.
8–12
 For protecting water ecosystems,44 
effect-based in vitro assays have been increasingly used for water quality monitoring. For 45 
example, in the EU SOLUTIONS project, a suite of in vitro assays, which represent different 46 
cellular toxicity pathway including nuclear hormone receptors mediated effects (e.g. estrogen 47 
(ER), androgen (AR), progesterone (PR), glucocorticoid (GR), or thyroid (TR) receptor 48 
reporter gene assay), xenobiotic metabolism, mutagenicity, genotoxicity, oxidative stress, and 49 
cell viability, was applied.
13–16
 These in vitro assays can provide useful information for the50 
assessment of the mixture of hazardous chemicals present in the aquatic environment. 51 
However, until now, cellular toxicity pathway via G protein-coupled receptors (GPCRs) have 52 
not been considered in water quality monitoring. GPCR is the largest group of cell surface 53 
receptors, and participate in various physiological and pathophysiological processes. It is 54 
estimated that nearly 40% of all marketed pharmaceuticals act by binding to GPCRs.
17, 18
55 
In 2012, the in vitro transforming growth factor-α (TGFα) shedding assay, which is a 56 
high-throughput and sensitive assay to detect both agonism and antagonism of GPCRs, was 57 
developed.
19
 So far, we have demonstrated that the TGFα shedding assay is useful to detect58 
biological activity of GPCR-acting pharmaceuticals in wastewater.
20
 Secondary effluent (SE)59 
of WWTPs in Japan were extracted by the solid-phase extraction (SPE), and applied to the 60 
assay. As a result, antagonistic activities of several classes of GPCR-acting pharmaceuticals 61 
against angiotensin (AT1), dopamine (D2), adrenergic family members (β1), muscarinic 62 
acetylcholine (M1), and histamine (H1) receptors were detected for the first time.
20
 However,63 
so far, only our research group have applied the TGFα shedding assay to environmental 64 
waters; the situation in other countries remains unclear. 65 
Contamination of wastewater with GPCR-acting pharmaceuticals is probably more 66 
serious in developed countries than in developing countries because 1) in general, the higher 67 
the country’s gross domestic product, the higher the health expenditure including the cost of 68 
pharmaceuticals
21, 22
; 2) some classes of GPCR-acting pharmaceuticals (e.g., antagonists 69 
against AT1 or β1 receptors) are used to treat ageing-related and chronic disease such as 70 
hypertensive
23
; and 3) the percentage of elderly population in developed countries (e.g., Japan, 71 
Europe, and North America) are higher than those in developing countries (e.g., Africa and 72 
Latin America).
24
 Pharmaceuticals which target other GPCRs are also expected to be73 
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consumed more in developed countries than in developing countries. For example, 74 
antagonists against D2 receptor (e.g., antipsychotics) are used to treat schizophrenia
23
,75 
depressive disorders and dementia.
25
 Antagonists against H1 receptor (e.g., antihistamines)76 
are preliminary used to treat immunoglobulin E (IgE) immediate allergies.
23
77 
In this study, we aimed to investigate whether biological activities of GPCR-acting 78 
pharmaceuticals against AT1, D2, β1, M1, and H1 receptors could be detected by the TGFα 79 
shedding assay in wastewater in another developed country besides Japan. So far, our 80 
research group has investigated the occurrence of micropollutants in wastewater in the UK by 81 
chemical analysis
26, 27
, and has established a system and facilities to conduct field surveys82 
there. This is why we selected the UK as a research field in this study. To achieve the 83 
objective of this study, we conducted three experiments:  84 
1) Detect and quantify agonistic and antagonistic activities against AT1, D2, β1, M1, and H185 
receptors in effluent extracts from two UK activated sludge plants over the period 2014-16. 86 
As a reference, we also detect and quantify the activities in effluent from an activated sludge 87 
plant in Japan in 2015-16. 88 
2) Determine to what extent sulpiride (a D2 receptor antagonist) and pirenzepine (an M189 
receptor antagonist) can explain the antagonistic activities at the D2 and M1 receptors, 90 
respectively 91 
3) Determine to what extent propranolol, metoprolol and atenolol (antagonists for β192 
receptor) can jointly explain the antagonistic activities at β1 receptor 93 
Based on the activity of known agonist and corresponding antagonistic pharmaceuticals, 94 
activity detected in the effluent extracts were quantified as agonist or antagonist equivalent 95 
quantities (EQs), respectively. For antagonistic activity, valsartan (an antagonist for AT1 96 
receptor), sulpiride, propranolol, pirenzepine, and diphenhydramine (an antagonist for H1 97 
receptor) were used as reference pharmaceuticals for each GPCR, i.e., valsartan-EQ for AT1, 98 
sulpiride-EQ for D2, propranolol-EQ for β1, pirenzepine-EQ for M1, and diphenhydramine-99 
EQ for H1 receptors, respectively. 100 
In parallel to the TGFα shedding assay, concentrations of sulpiride, pirenzepine, and 101 
metoprolol, atenolol and propranolol (β-blockers) in effluents in UK were measured by 102 
chemical analysis. Thus, we determined to what extent these known pharmaceuticals could 103 
explain the antagonistic activities for D2, M1 and β1 receptors, respectively. 104 
105 
MATERIALS AND METHODS 106 
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Chemicals 107 
The chemicals used in this study are described in Supporting Information (SI) Methods S1. 108 
Sampling and sample treatment for biological and chemical analyses 109 
Sampling of WWTP effluents in UK was conducted as a part of field survey for the 110 
occurrence of pharmaceuticals and personal care products (PPCPs) in river basin and WWTPs 111 
in UK.
28, 29
 Final effluent samples were collected from two municipal WWTPs in UK from112 
2014 to 2016 (SI Table S1, Samples ID1‒4 and 5‒8 from UK1 and UK2, respectively). Both 113 
WWTPs use activated sludge as secondary treatment, whilst UK2 uses sand filtration as a 114 
tertiary treatment. Effluent from final settling tanks after activated sludge process (secondary 115 
effluent, SE) from one municipal WWTP in Japan was also collected from 2015 to 2016 116 
(Samples ID9‒12 from JPN1). The characteristics of each WWTP are also summarized in SI 117 
Table S1. 118 
For biological analysis, a total 3 L of each sample was collected in amber glass bottles, to 119 
which 1 g/L ascorbic acid was added as preservative. After collection, UK samples (ID1‒8), 120 
and Japan samples (ID9‒12) were transported to the laboratory in Centre for Ecology and 121 
Hydrology in UK or Kyoto University in Japan, respectively. All the samples were filtered 122 
and extracted within 24 h. The samples were stored at 4 °C before filtration. 123 
Samples for the TGFα shedding assay were extracted by SPE as previously described (SI 124 
Methods S2).
30
 These effluent extracts were serially diluted, and then applied to the TGFα125 
shedding assay. The concentrations of effluent extracts during cell exposure were defined in 126 
terms of the relative enrichment factor (REF: the ratio of the enrichment factor (from the SPE 127 
step) to the dilution factor of the effluent extracts in the TGFα shedding assay). The Milli-Q 128 
water was also extracted by SPE in parallel as a blank control both in the laboratories in UK 129 
and Japan, which we confirmed to have no agonistic or antagonistic activity by the TGFα 130 
shedding assay. 131 
Selection of GPCRs 132 
We selected AT1, D2, β1, M1, and H1 receptors (Table 1), because strong antagonistic 133 
activities against these receptors were detected in effluent from WWTPs in Japan in our 134 
previous study.
20
 We also selected a number of receptors in the same classes as these (D4, β3, 135 
M3, and H2), in order to compare the receptor specificity of the biological activity of the 136 
effluent extracts. 137 
Agonists and antagonists used in this study 138 
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For each GPCR, known agonists and corresponding antagonists were used as positive controls 139 
for the bioassays, and as reference compounds for activity quantification (Table 1 and SI 140 
Methods S1). The activity of all the tested agonists and antagonists for AT1, D2, β1, M1 and 141 
H1 receptors had already been quantified by the TGFα shedding assay in our previous study.
20
142 
In this study, agonist tests were repeated for each agonist. 143 
In our previous study, olmesartan medoxomil (OM) was used as the standard antagonistic 144 
pharmaceutical against AT1 receptor to represent the antagonistic activity against AT1 145 
receptor in effluent extracts.
20
 However, in this study, valsartan was used as a standard instead146 
of OM. Because OM is a pro-drug for olmesartan, its active form, OM is not appropriate as a 147 
standard. 148 
Some antagonists were applied to multiple receptors belonging to the same class (D4, β3, 149 
M3, and H2) to confirm that the TGFα shedding assay could detect the specificity of receptor-150 
antagonist binding affinities as previously described.
20
151 
152 
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Table 1. GPCRs and standard chemicals used in this study, and their EC50, EC20, IC50, 153 
IC20, and relative potency values 154 
Receptor class 
Receptor 
name 
Agonist used 
[abbr.] 
EC50(agonist) 
(M) 
EC20(agonist)
a
(M) 
Antagonist used 
[abbr.] 
IC50(antagonist) (M) 
IC20(antagonist
 
)
a (M) 
Angiotensin II AT1 
Angiotensin 
II [ANG II] 
3.4 × 10-10 8.2 × 10-11
Valsartan 
[VAL] 
2.9 × 10-9 7.2 × 10-10 
Dopamine 
D2 
Dopamine 
[DA] 
6.7 × 10-9 1.8 × 10-9 
Sulpiride 
[SUL] 
1.9 × 10-7 4.4 × 10-8 
D4 1.6 × 10-8 b 6.8 × 10-6 
Adrenoceptor 
β1 
Isoproterenol 
[ISO] 
3.2 × 10-8 8.1 × 10-9 
Propranolol 
[PRO] 
8.1 × 10-9 
(RP = 1.0 c) 
2.1 × 10-9 
Metoprolol 
[MET] 
6.4 × 10-8 
(RP = 1.3 × 10-1 
c) 
Atenolol 
[ATE] 
4.2 × 10-7 
(RP = 2.0 × 10-2 
c)
β3 2.9 × 10-6 b PRO 2.5 × 10-6 
Acetylcholine 
M1 
Acetylcholine 
[ACh] 
4.4 × 10-8 1.2 × 10-8 
Pirenzepine 
[PIR] 
2.6 × 10-8 6.5 × 10-9 
M3 5.4 × 10-9 b 2.0 × 10-6 
Histamine 
H1 
Histamine 
[HIS] 
1.2 × 10-8 3.2 × 10-9 
Diphenhydramine 
 [DIP] 
2.5 × 10-7 5.5 × 10-8 
H2 8.1 × 10-8 b ＞ 10-5 d 
a: EC20(agonist) and IC20(antagonist) of reference compounds only for AT1, D2, β1, M1, and H1 155 
receptors are shown here, which were used to calculate agonist equivalent quantities (EQs) or 156 
antagonist EQs of wastewater extracts. 157 
b: Data was cited from our previous study.
20
158 
c: Relative potency (RP) = IC50(propranolol) / IC50(propranolol, metoprolol or atenolol). 159 
d: Inhibition of AP-TGFα release was not observed at the test concentration. 160 
161 
In vitro TGFα shedding assay 162 
The principle of the TGFα shedding assay for agonistic activity is agonist-induced 163 
accumulation of alkaline phosphatase-tagged TGFα (AP-TGFα), a reporter enzyme, in the 164 
media harvested from cultured cells (i.e., conditioned medium (CM)). The TGFα shedding 165 
assay was conducted as previously described
19,
 
20
 with slight modifications (SI Methods S3).166 
Briefly, GPCR-expressing plasmid was transiently transfected into a cultured cell line (HEK 167 
293 cells). By selecting the GPCR expression plasmid in cells, we can measure agonistic and 168 
antagonistic activities against each GPCR. Transfected cells were reseeded in a 96-well plate, 169 
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and then exposed to a reference compound or effluent extract 1 h. Accumulation of AP-TGFα 170 
in the CM (AP-TGFα release (%)) was calculated, and then normalized to the maximum 171 
activity of the reference agonist (SI Methods S4 and Figure S1A and B). Dose–response data 172 
were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, 173 
USA). Then, agonistic effects of the effluent extracts were determined as an agonist 174 
equivalent quantities (EQ) (SI Methods S5 and Figure S2A and B). When the AP-TGFα 175 
release from a given effluent extract reached >20% of the maximum AP-TGFα release 176 
induced by the corresponding agonist (e.g., ANG II for AT1 receptor), it was defined as 177 
‘detected’. 178 
For antagonistic activity, cells were pretreated with the test antagonist or effluent extract 179 
5 min before stimulation with a known agonist corresponding to the tested GPCR. 180 
Concentrations of corresponding agonists (angiotensin II for AT1, dopamine for D2, 181 
isoproterenol for β1, acetylcholine for M1, and histamine for H1 receptors) are equal to the 182 
concentrations that induce more than 80% activation of each receptor (i.e., EC80). If 183 
antagonistic pharmaceuticals are present in the effluent extracts, agonist-induced AP-TGFα 184 
release decrease. Accumulation of AP-TGFα in the CM (AP-TGFα release (%)) was 185 
calculated, and then normalized to the maximum activity of the reference agonist (SI Methods 186 
S4 and Figure S1C and D). The antagonistic effects of the effluent extracts were determined 187 
as an antagonist EQ (SI Methods S5 and Figure S2C and D). When agonist-induced AP-188 
TGFα release was inhibited by a given effluent extract by >20%, it was defined as ‘detected’. 189 
All assays were performed in triplicate for all GPCRs. In the case of GPCRs for which 190 
agonist and/or antagonistic activity was detected in wastewater extracts, assays were 191 
performed at least twice, and total 6–9 data sets were obtained. 192 
Before being analyzed for agonistic and antagonistic activity, the dilution range of 193 
effluent extracts in which GPCR-acting pharmaceuticals in effluent extracts show the specific 194 
interaction with a GPCR was determined in mock transfection condition test (SI Methods S6). 195 
The cytotoxicity of each effluent extract was analyzed by the Cell Counting Kit-8 (CCK-8; 196 
Dojindo Molecular Technologies, Japan).
31
 Based on the results, we conducted the TGFα197 
shedding assay on effluent extracts with a maximum REF value of 63.2 (ID1–3, 6, 7, and 9–198 
12) or 20 (ID4, 5, and 8) (SI Figure S3). We confirmed that the Milli-Q water extract showed199 
neither activity under mock transfection conditions nor cytotoxicity at all dilutions (data not 200 
shown). 201 
Data presentation for in vitro assay 202 
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EC20, IC20, agonist EQ, and antagonist EQ of wastewater extracts were calculated using the 203 
linear concentration-effect curves approach as previously described
14, 32–34
 with slight204 
modification (SI Methods S5 and Figure S2). Briefly, the linear part of the concentration–205 
effect curves was used to determine the EC20 value of each effluent extract (EC20(extract): the 206 
REF that gave a 20% activation) and IC20 value of each effluent extract (IC20(extract): the REF 207 
that gave a 20% reduction of agonist-induced AP-TGFα release) (SI Figure S2). The EC20208 
value of the corresponding agonist (EC20(agonist)) and the IC20 value of the corresponding 209 
antagonist (IC20(antagonist)) were determined from the dose–response curves of corresponding 210 
agonists and antagonists (SI Figure S4). The agonist EQ (ng-agonist-EQ/L) for each GPCR 211 
was then determined as EC20(agonist)/EC20(extract). Similarly, antagonist EQ (ng-antagonist-EQ/L) 212 
was determined as IC20(antagonist)/IC20(extract). For each GPCR, the limit of detection (LOD) for 213 
agonist EQ and antagonist EQ were determined based on the EC20(agonist) and IC20(antagonist), 214 
respectively (SI Methods S5). 215 
Calculation of relative potency value of propranolol, metoprolol and atenolol, and 216 
predicted propranolol-EQs values 217 
For β1 receptor, we measured and compared biological activities of three β-blockers, 218 
metoprolol, atenolol, and propranolol, by the TGFα shedding assay. Propranolol showed the 219 
highest activity among these three β-blockers (see Results and Discussion). Therefore, 220 
propranolol was used as a reference pharmaceutical to calculate antagonist EQ of effluent 221 
extracts for β1 receptor in the TGFα shedding assay (i.e., propranolol-EQ). Relative potency 222 
(RP) values of propranolol, metoprolol and atenolol were determined as IC50(propranolol) / 223 
IC50(propranolol, metoprolol or atenolol). Predicted propranolol-EQs of effluent extracts were calculated 224 
based on the concentration addition model from the molar concentrations (mol/L) of 225 
propranolol, metoprolol, and atenolol by chemical analysis, and their RP values (SI Methods 226 
S7). 227 
Recovery of antagonistic activities during solid-phase extraction 228 
Before applying the TGFα shedding assay to wastewater extracts, recovery rates of activity of 229 
reference GPCR-acting pharmaceuticals for AT1, D2, β1, M1, and H1 receptors during the 230 
SPE procedure for the TGFα shedding assay were investigated. We tested the recovery of 231 
activities of valsartan, sulpiride, propranolol, pirenzepine and diphenhydramine by spike 232 
testing (SI Methods S8). 233 
Chemical analysis of pharmaceuticals 234 
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Six UK samples (ID1–4, 7, and 8) were collected for chemical analysis in parallel with the 235 
samples for the TGFα shedding assay, and extracted by the SPE procedure. These sampling 236 
were conducted as a part of field survey
28, 29
, where the concentrations of 53 PPCPs in river237 
basin and WWTPs in UK were measured by ultra-performance liquid chromatography 238 
coupled with tandem mass spectrometry (UPLC/MS/MS) and quantified using the recovery of 239 
corresponding or representative surrogate internal standard as previously described.
35
240 
Concentration data of sulpiride, pirenzepine, propranolol, metoprolol and atenolol are shown 241 
in our previous study.
28
 We used these concentration data in this present study. Thus, the242 
sulpiride-EQ, pirenzepine-EQs, and propranolol-EQ measured by the TGFα shedding assay 243 
were compared with concentrations of sulpiride, pirenzepine, and three β-blockers to 244 
determine to what extent these known pharmaceuticals could explain the antagonistic 245 
activities for D2, M1 and β1 receptors, respectively. 246 
Statistical analysis 247 
The significance of the difference of antagonistic EQs measured by the TGFα shedding assay 248 
between UK1 and JPN1 WWTPs, and UK2 and JPN1 WWTPs were assessed by t-test, 249 
respectively, using GraphPad Prism 5 software. 250 
251 
RESULTS AND DISCUSSION 252 
Activity of known agonists and antagonists 253 
The concentration–response curves of reference agonist are shown in SI Figure S4 (Agonist). 254 
The EC50(agonist) and EC20(agonist) values were calculated from these curves (Table 1), and used 255 
to calculate the agonist EQs of the effluent extracts. Similarly, the concentration–response 256 
curves of reference antagonist are shown in SI Figure S4 (Antagonist). The IC50(antagonist) and 257 
IC20(antagonist) values were calculated from these curves (Table 1), and used to calculate the 258 
antagonist EQs of the effluent extracts. 259 
As for the β1 receptor, antagonistic activities of three β-blockers, propranolol, metoprolol, 260 
and atenolol, were analyzed by the TGFα shedding assay (SI Figure S4, Antagonist, β1). The 261 
most potent was found to be propranolol (Table 1, IC50 value: 8.1 × 10
-9
M) followed by262 
metoprolol (IC50 value: 6.4 × 10
-8
 M) and atenolol (IC50 value: 4.2 × 10
-7
 M). This trend is263 
consistent with previous studies showing the binding affinity of β-blockers to β1 receptor.
36, 37
264 
Therefore, propranolol was used as a standard antagonistic pharmaceutical in this study. 265 
Relative potency values of propranolol, metoprolol, and atenolol to propranolol are calculated 266 
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to be 1.0, 1.3 × 10
-1
, and 2.0 × 10
-2
, respectively (Table 1).267 
Some antagonists were applied to multiple receptors belonging to the same class (SI 268 
Figure S4, D4, β3, M3, and H2). For example, diphenhydramine was applied to H1 and H2 269 
receptors. The results show that the TGFα shedding assay could detect the specificity of 270 
receptor-antagonist binding affinities as previously described.
20
271 
Recovery rates of antagonistic activity by the SPE cartridge 272 
Recovery rates of antagonistic activity against each GPCR are shown in SI Figure S5. The 273 
recovery of all the tested pharmaceuticals in the Milli-Q water was higher than 70% (SI 274 
Figure S5A and B, Milli-Q). Recoveries of antagonistic activity of valsartan, propranolol, and 275 
diphenhydramine in SE were 77, 70, and 72%, respectively (SI Figure S5A, SE). These 276 
results indicate that recoveries of antagonistic activities against AT1, β1, and H1 receptors 277 
during the SPE procedure used for the TGFα shedding assay are acceptable.
38
 Therefore, in278 
this study, antagonist EQs for these receptors measured by the TGFα shedding assay were not 279 
corrected for their activity recoveries. Propranolol-EQs measured by the assay were directly 280 
compared with the predicted propranolol-EQs based on the concentrations of propranolol, 281 
metoprolol, and atenolol measured by chemical analysis (see below). 282 
For the D2 receptor, when 5.0 × 10
4
 of sulpiride were spiked into effluent, recovery was283 
only 42%, however, it was improved to 89% when the spiked concentration was reduced to be 284 
5.0 × 10
2
 ng/L (SI Figure S5B, sulpiride). Similarly, for M1 receptor, the recovery of activity 285 
was only 45% when 2.0 × 10
4
 of pirenzepine were spiked into effluent, however it was 286 
improved to be 82% when the spiked concentration was reduced to be 2.0 × 10
2
 ng/L (SI 287 
Figure S5B, pirenzepine). These results indicate that for D2 and M1 receptors, at a few 288 
hundred ng-antagonist-EQ/L, recovery of antagonistic activities during the SPE procedure is 289 
acceptable
38
, and sulpiride-EQs or pirenzepine-EQs measured by the assay are directly290 
comparable to the concentrations of sulpiride or pirenzepine by chemical analysis, 291 
respectively. 292 
Agonistic and antagonistic activities found in the effluent extracts 293 
For all the effluent samples, the concentration–response curves of agonistic activity, and the 294 
concentration–inhibition curves of antagonistic activity were obtained from the results of the 295 
TGFα shedding assay (SI Figures S6, S7, and S8 for effluent extracts from UK1, UK2, and 296 
JPN1 WWTPs, respectively). The linear form of the concentration–effect curves was used to 297 
determine EC20 and IC20 values for each wastewater extract (SI Figures S9 and S10 for UK1, 298 
Figures S11 and S12 for UK2, and Figures S13 and S14 for JPN1). The Milli-Q water extract 299 
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showed no response with all the tested GPCRs (data not shown), which demonstrates that all 300 
the agonistic and antagonistic activity was wastewater-specific. 301 
Agonistic activities were detected only with the D2, β1, and M1 receptors in the effluent 302 
extract from UK2 WWTP in September 2014 (SI Figure S11, ID6, H) and August 2015 (ID8, 303 
Q–S). In other samples, agonistic activities were lower than LOD with tested GPCRs (SI 304 
Figures S9, S11, and S13). 305 
In the antagonistic test, effluent extracts from UK1 WWTP (ID1–4) showed the inhibition 306 
of agonist-induced AP-TGFα release with all tested GPCRs frequently through the sampling 307 
campaign (SI Figure S10). Effluent extracts from UK2 WWTP (ID5–8) also frequently 308 
showed antagonistic activities against AT1, D2, β1, and H1 receptors, but only one occasion 309 
for M1 (SI Figure S12). Effluent extracts from JPN1 WWTP (ID9–12) also showed 310 
antagonistic activities against all GPCRs (SI Figure S14). Notably, antagonistic activities 311 
against AT1 and H1 receptors were strong in all the samples: IC20 values were lower than 312 
those for other receptors (SI Figure S14A, F, K, and P for AT1 receptor, and E, J, O, and T 313 
for H1 receptor). 314 
We confirmed the receptor specificity of antagonistic activity detected in effluent 315 
extracts (SI Figure S15). For example, sample ID1 showed antagonistic activities against D2, 316 
β1, M1, and H1 receptors but no antagonistic activity was observed against receptors in the 317 
same class, which shared the same endogenous agonists (D4, β3, M3, and H2). The results 318 
show that antagonistic activities against AT1, D2, β1, M1 and H1 in Japan as well as UK 319 
samples were receptor specific. These results indicate that activities were attributable to 320 
highly selective GPCR-acting pharmaceuticals, but not to nonreceptor-mediated pathway, 321 
such as adsorption of the agonist by large organic molecules, as previously described.
20
322 
Agonist and Antagonist equivalents of effluent extracts 323 
From the linear concentration–effect curves of agonistic activity of the effluent extract from 324 
UK2 WWTP in September 2014 and August 2015 (SI Figure S11, ID6 and 8), agonist EQ 325 
values were calculated: 19 ng-DA-EQ/L for D2 receptor, 43 and 1.3 × 10
2
 ng-ISO-EQ/L for326 
β1 receptor, and 1.2 × 10
2
 ng-ACh-EQ/L for M1 receptor, respectively (SI Table S2).327 
From the linear concentration–effect curves of antagonistic activity (SI Figures S10, S12, 328 
and S14), antagonist EQ values were calculated for the effluent extracts (Figure 1, and SI 329 
Table S3). For AT1 receptor, valsartan-EQs in effluents from the JPN1 WWTP (Figure 1, 330 
AT1, 3.5 × 10
2
–4.0 × 10
2
 ng-VAL-EQ/L) were significantly higher than those in UK1 (36–331 
1.1 × 10
2
 ng-VAL-EQ/L) (p < 0.001, t-test) and UK2 WWTPs (22–1.9 × 10
2
 ng-VAL-EQ/L)332 
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(p = 0.0004, t-test). Similarly, for H1 receptor, diphenhydramine-EQs in the effluent from the 333 
JPN1 WWTP (4.1 × 10
3
–5.8 × 10
3
 ng-DIP-EQ/L) were significantly higher than those in the 334 
UK1 (1.7 × 10
3
–2.0 × 10
3
 ng-DIP-EQ/L) (p = 0.0003, t-test) and the UK2 WWTPs (8.1 × 335 
10
2
–1.5 × 10
3
 ng-DIP-EQ/L) (p = 0.0001, t-test). For the D2 receptor, sulpiride-EQs were at 336 
similar levels among UK1 (4.8 × 10
2
–1.5 × 10
3
 ng-SUL-EQ/L), UK2 (4.9 × 10
2
–1.2 × 10
3
 ng-337 
SUL-EQ/L), and JPN1 WWTPs (3.7 × 10
2
–1.2 × 10
3
 ng-SUL-EQ/L). Similarly, for β1338 
receptor, the propranolol-EQs were at similar levels among UK1 (41–62 ng-PRO-EQ/L), 339 
UK2 (40–47 ng-PRO-EQ/L), and JPN1 WWTPs (38–56 ng-PRO-EQ/L). For the M1 receptor, 340 
antagonistic activities were detected for all samples in JPN1 (89–2.5 × 10
2
 ng-PIR-EQ/L) and341 
for three samples in UK1 (53–80 ng-PIR-EQ/L), but detected in only one sample in UK2 (49 342 
ng-PIR/L). For both the UK and Japan samples, the antagonist EQs for the H1 receptor had 343 
the highest activity among the five GPCRs tested in this study, followed by D2 and AT1, and 344 
then finally β1 and M1 receptors. 345 
Agonistic activity was detected only in the UK2 WWTP in September 2014 (ID6) and 346 
August 2015 (ID8). In contrast, antagonistic activity was detected in many effluent extracts 347 
from WWTPs in both the UK and Japan against all GPCRs tested in this study. These greater 348 
detection frequencies of antagonistic activity than agonistic activity coincide well with the 349 
results in our previous study focusing on Japan.
20
 This might be expected since most of the350 
currently marketed GPCR-acting pharmaceuticals are antagonists
20 
based on the information351 
on the DrugBank online database. Mixture effects between the agonist and antagonistic 352 
activity also might play a part (see below next section).353 
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354 
355 
Figure 1. Summary of antagonistic activities of wastewater extracts. 356 
Plots represent mean ± SEM, n = 6. Lines are limit of detection (LOD) of activities. VAL: valsartan; 357 
SUL: sulpiride; PRO: propranolol; PIR: pirenzepine; DIP: diphenhydramine. 358 
359 
Comparison between antagonist equivalents derived from the bioassay and measured 360 
concentrations of corresponding pharmaceuticals 361 
Concentrations of sulpiride, pirenzepine, propranolol, metoprolol and atenolol in UK samples 362 
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(ID1–4, 7, and 8) were measured by UPLC/MS/MS in parallel with the TGFα shedding assay. 363 
Concentration values are used from our previous study
28
 (SI Table S4). Sulpiride-EQs in 364 
samples ID1–4, 7, and 8 measured by the TGFα shedding assay (4.8 × 10
2
–1.5 × 10
3
 ng-SUL-365 
EQ/L) were at least 5 times higher than concentrations of actual sulpiride measured in these 366 
samples (15–1.2 × 10
2
 ng/L) (Figure 2, D2). In addition, at thousands ng-SUL-EQ/L level,367 
some parts of sulpiride-EQ might be loss during SPE process (SI Figure S5). Similarly, 368 
pirenzepine-EQs in samples ID1–3 measured by the assay (53–80 ng-PIR-EQ/L) were at least 369 
10 times higher than concentrations of pirenzepine measured by chemical analysis in these 370 
samples (0.5, 6.1 and 3.8 ng/L) (Figure 2, M1). These results indicate that, at least two 371 
WWPTs in the UK investigated in this study, besides sulpiride or pirenzepine, other D2 or 372 
M1 antagonistic pharmaceuticals occur in wastewater (see below “Pharmaceuticals 373 
potentially responsible for the observed AT1, H1, D2, M1 and β1 receptors activity” section). 374 
375 
376 
377 
378 
379 
380 
381 
382 
383 
Figure 2. Comparison between sulpiride-EQs and concentration of sulpiride (antagonist for D2 384 
receptor), and pirenzepine-EQs and concentration of pirenzepine (antagonist for M1 385 
receptor). 386 
Antagonistic activities against M1 receptor in samples ID4, 5, 7, and 8 were below LOD. Therefore, 387 
pirenzepine-EQs for samples ID1–3 are compared with concentration of pirenzepine. Lines are 388 
the ratios of the concentrations to the EQs. For example, sulpiride-EQs deviate upward from 1:5 389 
line (D2), which indicates sulpiride-EQs are more than 5-time higher than concentration of 390 
sulpiride. SUL: sulpiride; PIR: pirenzepine. 391 
392 
Predicted propranolol-EQs for samples ID1–4, 7, and 8 based on the measured 393 
concentrations of propranolol, atenolol and metoprolol by chemical analysis were compared 394 
with the measured propranolol-EQs from the TGFα shedding assay (Figure 3). The 395 
Page 16 of 26Environmental Science & Technology
contribution of propranolol to predicted propranolol-EQs was dominant (gray bars), which 396 
indicate that, between the different putative β-blockers, propranolol was the most important in 397 
causing antagonistic activity against β1 receptor in wastewater in the UK. For samples ID1, 2, 398 
4, and 8, measured propranolol-EQs were lower than the predicted propranolol-EQs. This 399 
might be due to the competition between agonist and antagonistic activity in these effluent 400 
extracts. In the case of endocrine disrupting chemicals, it has been demonstrated that 401 
estrogenic and antiestrogenic compounds compete for the estrogen receptor (ER) in 402 
wastewater, and, as a result, the observed estrogenic activity is less than the predicted 403 
activity.
30, 39
 Similarly, agonist and antagonist compounds operating at the β1 receptor might 404 
compete with each other leading to the observed propranolol-EQ being less than predicted. 405 
406 
407 
408 
409 
410 
411 
412 
413 
414 
Figure 3. Comparison between predicted propranolol-EQs and measured 415 
propranolol-EQs.  416 
Predicted propranolol-EQs of samples ID1–4, 7, and 8 were calculated based on the concentrations 417 
of propranolol, metoprolol, and atenolol in these samples (SI Table S4), and their relative potency 418 
(RP) values. Propranolol is not considered to calculate predicted propranolol-EQs for samples ID3 and 419 
7, because the concentration data is not available for these samples. RP values of propranolol, 420 
metoprolol, and atenolol to propranolol are 1.0, 1.3× 10-1, and 2.0× 10-2, respectively. Measured 421 
propranolol-EQ values are from SI Table S3. 422 
423 
Comparison of biological activities of GPCR-acting pharmaceuticals in effluent extracts 424 
among WWTPs 425 
The antagonistic activities against for all GPCRs were found at similar levels between UK1 426 
and UK2 WWTPs (Figure 1). For D2 and β1 receptors, the antagonistic activities in JPN1 427 
were also found at similar levels with UK1 and UK2 WWTPs (Figure 1, D2 and β1). On the 428 
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other hand, activities against AT1 and H1 receptors in JPN1 were significantly higher than 429 
those in UK1 and UK2 (Figure 1, AT1 and H1). The characteristic of individual WWTPs 430 
covered in this study, such as the type of influents (i.e., municipal wastewater), the population 431 
equivalent served, and the treatment efficiency, were comparable (SI Table S1). Therefore, 432 
the differences observed in the TGFα shedding assay might come from the different usage 433 
patterns of pharmaceuticals between the UK and Japan. For example, pharmaceuticals which 434 
target the AT1 receptor, antihypertensive, might be consumed more in Japan than UK because 435 
of the higher proportion of the population of elderly people (age ≥ 60) in Japan (33%) 436 
compared to that of the UK (24%).
24
437 
The higher activity against the H1 receptor found in JPN1 compared to those in UK1 and 438 
UK2 might be due to the sampling in the UK in different seasons (in summer and winter) 439 
from that in Japan (in spring). In spring, about 27% of Japanese people suffer from hay-fever, 440 
particularly with cedar pollinosis, and take H1 antagonists to treat its symptoms.
40, 41
 If we441 
took wastewater in the UK in spring, antagonistic activity against the H1 receptor in UK 442 
WWTPs might be as high as that in Japan. 443 
Pharmaceuticals potentially responsible for the observed AT1, H1, D2, M1 and β1 444 
receptors activity 445 
So far, one AT1 receptor antagonist (valsartan), and three H1 antagonists (diphenhydramine, 446 
fexofenadine, and loratadine) have been detected in wastewater in the UK by chemical 447 
analysis.
42–45
 In Japan, two AT1 receptor antagonists (losartan and candesartan)
46
 and one H1 448 
receptor antagonist (diphenhydramine)
46, 47
 have been detected. Other AT1 receptor 449 
antagonists (e.g., olmesartan, irbesartan, telmisartan, and eprosartan)
48–51
, and H1 receptor 450 
antagonists (e.g., cinnarizine, cetirizine, cyproheptadine, and loratadine)
52
 have been detected 451 
in wastewater in other countries. Whilst in this study, the concentrations of these 452 
pharmaceuticals were not measured by chemical analysis, it is possible they were contributing 453 
to the antagonistic activities detected against the AT1 and H1 receptors. 454 
Although two H2 antagonists, ranitidine and cimetidine, have been detected in 455 
wastewater in the UK by chemical analysis at hundred to thousand ng/L range in previous 456 
studies
42, 43, 45
, H2 antagonistic activity was lower than LOD (3.0 × 10
2
 ng-famotidine-EQ/L)457 
in all samples tested for H2 activity here (SI Figure S15, H2). This gap might be due to 458 
differences in usage of pharmaceuticals in local catchment areas, differences in treatment 459 
efficiency of WWTP, low recovery of H2 antagonist during the SPE processing, and/or weak 460 
activity of H2 antagonists (SI Discussion S1). 461 
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Concentrations of sulpiride and pirenzepine could explain only small parts of sulpiride-462 
EQs and pirenzepine-EQs detected in effluent extracts in the UK, respectively (Figure 2). 463 
Looking at the pharmaceutical consumption data in the UK in 2014 that is available from the 464 
National Health Service (NHS) online database
53
, we can find many D2 receptor antagonists465 
besides sulpiride such as quetiapine, amisulpiride, domperidone, chlorpromazine, promazine, 466 
metoclopramide, promethazine, and olanzapine. Similarly, for the M1 receptor, other than 467 
pirenzepine, we can find many antagonists such as quetiapine and olanzapine (also known as 468 
D2 antagonists), solifenacin, flavoxate, trospium, oxybutynin, disopyramide, and tolterodine. 469 
These antagonistic pharmaceuticals might also contribute to the sulpiride-EQs and 470 
pirenzepine-EQs as well. Of these D2 and M1 antagonists, quetiapine, amisulpride, and 471 
olanzapine have been detected by chemical analysis in wastewater in other countries.
51, 54, 55
472 
However, other D2 and M1 antagonists have been overlooked and so far are not being 473 
measured by the chemical analysis. Attention should be paid to these pharmaceuticals for 474 
environmental monitoring in future studies. 475 
Agonistic activity was detected only in the UK sample which was collected at UK2 476 
WWTP in September 2014 (ID6) and August 2015 (ID8). Based on the pharmaceutical 477 
consumption data available from the NHS in the UK
53
, levodopa and pilocarpine, which are478 
agonistic pharmaceuticals against D2 and M1 receptors, respectively, are sold in the UK. 479 
These agonistic pharmaceuticals might contribute to the agonistic activity detected in the UK 480 
wastewater extracts. 481 
Future research needs in environmental monitoring and toxicity testing 482 
In this study, biological activity of GPCR-acting pharmaceuticals which act on AT1, D2, β1, 483 
M1, and H1 receptors were detected in wastewater in the UK by the TGFα shedding assay for 484 
the first time. Such activity is clearly not unique to wastewater in Japan. Further efforts to 485 
identify GPCR-acting pharmaceuticals responsible for the observed AT1, H1, D2, M1 and β1 486 
receptors activity in wastewater will be needed in future studies. Looking at the 487 
pharmaceutical consumption data (e.g., NHS online database in the UK) is a useful means of 488 
identifying new targets.  489 
In addition to the chemical concentration, knowledge of the activity (i.e., potency) of the 490 
individual chemicals is also required to be able to understand the adverse effects on aquatic 491 
organisms of GPCR-acting pharmaceuticals. Thus far, one AT1 antagonist (valsartan), six H1 492 
antagonists (diphenhydramine, cyproheptadine, azelastine, ketotifen, oxatomide, and 493 
pyrilamine), one D2 antagonist (sulpiride), three β1 antagonists (propranolol, metoprolol, and 494 
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atenolol), and one M1 antagonist (pirenzepine) have been analyzed for the potency using by 495 
the TGFα shedding assay in this study or in our previous studies.
19, 20
 However, other GPCR-496 
acting pharmaceuticals have not. This should be a subject of future study. 497 
Investigations of the mixture effect of GPCR-acting pharmaceuticals are also necessary 498 
to understand its adverse effects on aquatic organisms. The results of this study indicate that 499 
there might be a mixture effect between agonist and antagonistic activities against the β1 500 
receptor. Similarly, the mixture effect could occur in other GPCRs in complex environmental 501 
samples. 502 
503 
SUPPORTING INFORMATION 504 
Sampling information, summary of agonistic and antagonistic activities of effluent extracts, 505 
concentrations of antagonistic pharmaceuticals in effluents measured by chemical analysis, 506 
dose–response curves of known agonists and antagonistic pharmaceuticals, the results of 507 
mock transfection conditions experiments, dose–response curves of effluents from WWTPs in 508 
the UK and Japan, receptor specificity of effluents, methods for other experiments, and 509 
discussion about the absence of H2 receptor antagonistic activity in UK samples. This 510 
material is available free of charge at http://pubs.acs.org/. 511 
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